{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:18:42Z","timestamp":1776493122076,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T00:00:00Z","timestamp":1355961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00108-012-3204-5","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T13:24:59Z","timestamp":1355837099000},"page":"121-130","source":"Crossref","is-referenced-by-count":10,"title":["Schmerztherapie bei Morbus Fabry","Pain therapy for Fabry\u2019s disease"],"prefix":"10.1007","volume":"54","author":[{"given":"C.","family":"Sommer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Duning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Arning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Canaan-K\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Naleschinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"3204_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S11985","volume":"5","author":"Ramaswami","year":"2011","unstructured":"Ramaswami U (2011) Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther 5:155\u2013173","journal-title":"Drug Des Devel Ther"},{"key":"3204_CR2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","volume":"12","author":"Watt","year":"2010","unstructured":"Watt T, Burlina AP, Cazzorla C et\u00a0al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12:703\u2013712","journal-title":"Genet Med"},{"key":"3204_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","volume":"429","author":"MacDermot","year":"2001","unstructured":"MacDermot J, MacDermot KD (2001) Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 429:121\u2013125","journal-title":"Eur J Pharmacol"},{"key":"3204_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2362.2008.01921.x","volume":"38","author":"Weidemann","year":"2008","unstructured":"Weidemann F, Strotmann JM et\u00a0al (2008) Misleading terms in Anderson-Fabry disease. Eur J Clin Invest 38:191\u2013196","journal-title":"Eur J Clin Invest"},{"key":"3204_CR5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/mus.880040506","volume":"4","author":"Pellissier","year":"1981","unstructured":"Pellissier JF, Van Hoof F et\u00a0al (1981) Morphological and biochemical changes in muscle and peripheral nerve in Fabry\u2019s disease. Muscle Nerve 4:381\u2013387","journal-title":"Muscle Nerve"},{"key":"3204_CR6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ana.410230513","volume":"23","author":"Kaye","year":"1988","unstructured":"Kaye EM, Kolodny EH et\u00a0al (1988) Nervous system involvement in Fabry\u2019s disease: clinicopathological and biochemical correlation. Ann Neurol 23:505\u2013509","journal-title":"Ann Neurol"},{"key":"3204_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","volume":"145","author":"Torvin","year":"2009","unstructured":"Torvin Moller A, Winther Bach F et\u00a0al (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145:237\u2013245","journal-title":"Pain"},{"key":"3204_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/mus.21606","volume":"41","author":"Liguori","year":"2010","unstructured":"Liguori R, Di Stasi V et\u00a0al (2010) Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve 41:409\u2013412","journal-title":"Muscle Nerve"},{"key":"3204_CR9","doi-asserted-by":"crossref","unstructured":"Dutsch M, Marthol H et\u00a0al (2002) Small fiber dysfunction predominates in Fabry neuropathy. J\u00a0Clin Neurophysiol 19:575\u2013586","DOI":"10.1097\/00004691-200212000-00011"},{"key":"3204_CR10","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R et\u00a0al (2006) PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22:1911\u20131920","journal-title":"Curr Med Res Opin"},{"key":"3204_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2377-11-104","volume":"11","author":"Sommer","year":"2011","unstructured":"Sommer C, Richter H et\u00a0al (2011) A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol 11:104","journal-title":"BMC Neurol"},{"key":"3204_CR12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","volume":"23","author":"Lockman","year":"1973","unstructured":"Lockman LA, Hunninghake DB et\u00a0al (1973) Relief of pain of Fabry\u2019s disease by diphenylhydantoin. Neurology 23:871\u2013875","journal-title":"Neurology"},{"key":"3204_CR13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","volume":"39","author":"Filling-Katz","year":"1989","unstructured":"Filling-Katz MR, Merrick HF et\u00a0al (1989) Carbamazepine in Fabry\u2019s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 39:598\u2013600","journal-title":"Neurology"},{"key":"3204_CR14","doi-asserted-by":"crossref","unstructured":"Ries M, Mengel E et\u00a0al (2003) Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J\u00a0Inherit Metab Dis 26:413\u2013414","DOI":"10.1023\/A:1025127723729"},{"key":"3204_CR15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0887-8994(95)00007-3","volume":"12","author":"Gordon","year":"1995","unstructured":"Gordon KE, Ludman MD et\u00a0al (1995) Successful treatment of painful crises of Fabry disease with low dose morphine. Pediatr Neurol 12:250\u2013251","journal-title":"Pediatr Neurol"},{"key":"3204_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.33588\/rn.4903.2009100","volume":"49","author":"Politei","year":"2009","unstructured":"Politei JM (2009) Intravenous lidocaine as treatment for the painful episodes in Fabry\u2019s disease. Rev Neurol 49:166\u2013167","journal-title":"Rev Neurol"},{"key":"3204_CR17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK et\u00a0al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703\u2013710","journal-title":"Muscle Nerve"},{"key":"3204_CR18","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N et\u00a0al (2001) Safety and efficacy of recombinant human alpha-galactosidase\u00a0A-replacement therapy in Fabry\u2019s disease. N\u00a0Engl J Med 345:9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"3204_CR19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"Hoffmann","year":"2007","unstructured":"Hoffmann B, Beck M et\u00a0al (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2014a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535\u2013542","journal-title":"Clin J Pain"},{"key":"3204_CR20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"Hilz","year":"2004","unstructured":"Hilz MJ, Brys M et\u00a0al (2004) Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62:1066\u20131072","journal-title":"Neurology"},{"key":"3204_CR21","doi-asserted-by":"crossref","unstructured":"Roden DM (2008) Clinical practice. Long-QT syndrome. N\u00a0Engl J Med 358:169\u2013176","DOI":"10.1056\/NEJMcp0706513"},{"key":"3204_CR22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.amjmed.2009.12.022","volume":"123","author":"Weidemann","year":"2010","unstructured":"Weidemann F, Sommer C et\u00a0al (2010) Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge. Am J Med 123:658.e1\u2013658.e10","journal-title":"Am J Med"},{"key":"3204_CR23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"J","author":"Weidemann","year":"2005","unstructured":"Weidemann F, Breunig F et\u00a0al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart\u00a0J 26:1221\u20131227","journal-title":"Eur Heart"},{"key":"3204_CR24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"3204_CR25","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"Levey","year":"2005","unstructured":"Levey AS, Eckardt KU et\u00a0al (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089\u20132100","journal-title":"Kidney Int"},{"key":"3204_CR26","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/archinte.165.7.790","volume":"165","author":"Corsonello","year":"2005","unstructured":"Corsonello A, Pedone C et\u00a0al (2005) Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 165:790\u2013795","journal-title":"Arch Intern Med"},{"key":"3204_CR27","first-page":"647","volume":"107","author":"Hartmann","year":"2010","unstructured":"Hartmann B, Czock D et\u00a0al (2010) Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 107:647\u2013655","journal-title":"Dtsch Arztebl Int"},{"key":"3204_CR28","unstructured":"Baron R, Binder A et\u00a0al (2012) Pharmakologische nicht-interventionelle Therapie chronisch neuropathischer Schmerzen. In: Diener\u00a0HC, Putzki\u00a0N (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, 5.\u00a0Aufl. Thieme, Stuttgart"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-012-3204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-012-3204-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-012-3204-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:44:53Z","timestamp":1745441093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-012-3204-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["3204"],"URL":"https:\/\/doi.org\/10.1007\/s00108-012-3204-5","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,20]]}}}